VJHemOnc is committed to improving our service to you

ASH 2019 | Obinutuzumab plus len promising in untreated FL

VJHemOnc is committed to improving our service to you

Loretta Nastoupil

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results of the phase II trial (NCT01582776) of obinutuzumab, a monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC), with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). This drug combination was associated with high complete response and manageable toxicities. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter